ArticleRecent advances in drug delivery and formulation2026
Optimized Formulation of Sulfasalazine and Probiotic-Loaded Carrageenan Microparticles Using Design of Experiments for Effective Colitis Management.
Article in Recent advances in drug delivery and formulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUlcerative colitis (UC) is a chronic inflammatory bowel disease marked by mucosal inflammation and epithelial barrier dysfunction. Sulfasalazine, a standard antiinflammatory drug, and probiotics, known for gut microbiota modulation, have both shown efficacy in UC management. However, their combined delivery to the colon remains underexplored. This study aimed to develop a colon-targeted microparticulate formulation containing sulfasalazine and a probiotic strain to enhance anti-inflammatory action and therapeutic effectiveness against UC.
methodsMicroparticles were prepared using a Design of Experiments (DoE) approach, optimizing carrageenan and calcium chloride dihydrate concentrations and stirring speed. The probiotic was co-encapsulated to maintain viability during processing. In vitro evaluations included drug release studies and Caco-2 cell line assays for epithelial integrity, ROS generation, and NF-κB expression. In vivo efficacy was assessed using an acetic acid-induced colitis model, with evaluations based on inflammation severity, tissue damage and histopathology.
resultsOptimized microparticles ensured sustained sulfasalazine release and preserved probiotic viability. In vitro, the formulation improved epithelial barrier function, reduced ROS and proinflammatory cytokines, and suppressed NF-κB expression. In vivo, treated animals showed significant reduction in colitis severity, improved tissue integrity and better histopathological outcomes compared to controls. DISCUSSION: The combined sulfasalazine-probiotic microparticles effectively addressed both symptomatic relief and the inflammatory cascade in UC. Probiotics enhanced gut barrier protection, while sustained sulfasalazine release ensured localized therapeutic action. The synergy between drug and probiotic delivery offers a novel approach over conventional therapies.
conclusionThis study presents a promising colon-targeted microparticulate system combining sulfasalazine and probiotics for effective UC management. The dual-action formulation offers enhanced anti-inflammatory efficacy, reduced tissue damage, and better disease control, supporting its potential in future clinical applications.
Indexed as
Identifiers
40849760What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.